
LONDON, Jan 5 (Reuters) - Britain's medicines regulator said on Monday it was reviewing Novo Nordisk's NOVOb.CO application for an oral 25 milligram version of its weight-loss drug Wegovy and anticipated making a decision before the end of the year.
Novo is launching its once-daily Wegovy pill in the United States on Monday, hoping to regain ground lost to U.S. rival Eli Lilly LLY.N and attract new, needle-wary consumers.
The Danish drugmaker has previously said it submitted applications for the pill to the European Medicines Agency and other regulatory bodies in the second half of 2025.